Users Discontinuing Weight-Loss Injections Regain Weight at a Quadrupled Rate Than People Using Diet and Exercise

Fresh analysis indicates that individuals who discontinue new GLP-1 drugs like Mounjaro or Wegovy can put back on lost weight at a significantly accelerated pace than those who halt traditional lifestyle regimens.

Research printed in a major medical journal points out that while overweight individuals often shed substantial amounts of their total mass while undergoing treatment, the mass returns at an average rate of 0.8 kg per month once they quit.

"People purchasing such medications must be informed of the risk of rapid rebound weight gain when the treatment ends," stated researcher Dr. Susan Jebb.

That rate of recovery implies a reversion to pre-treatment mass within about one and a half years.

Weighing Approaches

The research, which examined 37 of trials involving over 9,000 of participants, compared the results of GLP-1 agonists with conventional dieting.

The team emphasize that individuals who lose weight through diet and exercise generally have a slower creep back—approximately 100 grams monthly—once they finish.

Understanding the Quick Rebound

Experts believe the way of the drugs accounts for the amplified rebound.

These medications imitate a natural hormone called glucagon-like peptide-1, which helps regulate feelings of fullness.

"Sustained high doses of the hormone concentrations far above than the body's typical production could lead to the system to produce less of its own natural hormone, and may also reduce responsiveness to its effects," explained Dr. Adam Collins, a nutrition researcher.

"Withdrawal of this medication results in appetite is no longer kept in check, making binge eating much more probable."

A Chronic Disease?

Medical guidelines recommend the jabs for individuals with weight-linked health risks, alongside prescribed diet and exercise modifications.

A number of clinicians say that, given the likelihood of relapse, the treatment should be considered ongoing.

This perspective is echoed by pharmaceutical companies, who state that the results "highlight the chronic nature of obesity," similar to managing diseases like high blood pressure.

Patient Accounts

People who have come off the medication describe a sudden resurgence of hunger.

"It felt as if a trigger that goes on and you're instantly starving," said a patient.

This difficulty is compounded if individuals have not developed lasting lifestyle or habit modifications during therapy.

Growing Adoption

Survey data show that a significant number of people in the UK have used weight-loss jabs in the last 12 months, with interest remaining high.

• Use is higher among females compared to men.
• The 40s and 50s demographic shows the greatest level of interest.
• A large proportion obtain the medications through private prescriptions rather than public health services.

Ultimately, researchers emphasize that while the jabs are powerful agents for shedding pounds, they are not a magic fix and lasting health benefits relies on integrated behavioural management.